Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Inventiva
  6. Summary
    IVA   FR0013233012

INVENTIVA

(IVA)
  Report
Real-time Euronext Paris  -  11:35:06 2023-02-03 am EST
5.850 EUR   +0.17%
02/02Inventiva : Corporate presentation February 2023
PU
01/30Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
GL
01/30Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/30/2023 01/31/2023 02/01/2023 02/02/2023 02/03/2023 Date
5.51(c) 5.65(c) 5.76(c) 5.84(c) 5.85(c) Last
37 481 14 649 11 420 16 209 10 762 Volume
-5.00% +2.54% +1.95% +1.39% +0.17% Change
More quotes
Estimated financial data (e)
Sales 2022 12,0 M 13,0 M 13,0 M
Net income 2022 -55,8 M -60,6 M -60,6 M
Net Debt 2022 13,1 M 14,2 M 14,2 M
P/E ratio 2022 -3,80x
Yield 2022 -
Sales 2023 3,16 M 3,43 M 3,43 M
Net income 2023 -78,6 M -85,3 M -85,3 M
Net Debt 2023 97,2 M 105 M 105 M
P/E ratio 2023 -2,84x
Yield 2023 -
Capitalization 246 M 267 M 267 M
EV / Sales 2022 21,6x
EV / Sales 2023 109x
Nbr of Employees 109
Free-Float 74,9%
More Financials
Company
Inventiva is a biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. The group is developing two drug candidates - lanifibranor and odiparcil - in non-alcoholic steatohepatitis (ź NASH ╗) and mucopolysaccharidosis (ź MPS ╗) respectively, as well as a... 
More about the company
Ratings of Inventiva
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about INVENTIVA
02/02Inventiva : Corporate presentation February 2023
PU
01/30Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
GL
01/30Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
GL
01/26Results of the votes of the Combined Shareholders' General Meeting of January 25, 2023
GL
01/26Results of the votes of the Combined Shareholders' General Meeting of January 25, 2023
GL
01/06Inventiva : Notice of meeting - Form 6-K
PU
01/05Inventiva : Corporate presentation January 2023
PU
01/04Inventiva Amends Clinical Program For Liver Disease Drug Amid US FDA's New Regulatory A..
MT
01/04Inventiva announces changes to the clinical development of lanifibranor, including plan..
GL
01/04Inventiva announces changes to the clinical development of lanifibranor, including plan..
AQ
01/04Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including..
CI
01/03Inventiva : GM January 25th, 2023 – Brochure
PU
01/03Inventiva : Combined General Meeting of January 25, 2023 – Availability of the prepa..
PU
01/03Inventiva : Report of the board of directors to the ordinary and extraordinary general mee..
PU
01/03Inventiva : Report on capital increase and cancellation of PSR
PU
More news
News in other languages on INVENTIVA
01/30Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Che..
01/26Résultats des votes de l'Assemblée Générale Mixte des actionnaires réunie le 25 janvier..
01/05Inventiva : des changements au plan sur la NASH
01/05Bolsa de Madrid: En los mercados, a Papá Noel se le agota el tiempo
01/05Sur les marchés, le Père Noël arrive à la bourre
More news
Analyst Recommendations on INVENTIVA
More recommendations
Chart INVENTIVA
Duration : Period :
Inventiva Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 5,85 €
Average target price 17,03 €
Spread / Average Target 191%
EPS Revisions
Managers and Directors
FrÚdÚric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial & Administrative Officer
Pierre Broqua Director, Chief Scientific Officer & Deputy CEO
Michael P. Cooreman Chief Medical Officer
Alice Roudot-Ketelers Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
INVENTIVA30.73%267
REGENERON PHARMACEUTICALS, INC.4.12%83 640
VERTEX PHARMACEUTICALS5.19%77 269
WUXI APPTEC CO., LTD.15.80%40 679
BIONTECH SE-5.43%34 523
BEIGENE, LTD.16.80%26 752